JP2019529581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529581A5 JP2019529581A5 JP2019540308A JP2019540308A JP2019529581A5 JP 2019529581 A5 JP2019529581 A5 JP 2019529581A5 JP 2019540308 A JP2019540308 A JP 2019540308A JP 2019540308 A JP2019540308 A JP 2019540308A JP 2019529581 A5 JP2019529581 A5 JP 2019529581A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- gain
- patient
- missense mutation
- function missense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 44
- 230000035772 mutation Effects 0.000 claims description 36
- 102100038595 Estrogen receptor Human genes 0.000 claims description 25
- 108010007005 Estrogen Receptor alpha Proteins 0.000 claims description 24
- 108020001756 ligand binding domains Proteins 0.000 claims description 18
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 12
- 239000003886 aromatase inhibitor Substances 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 238000009261 endocrine therapy Methods 0.000 claims description 9
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims description 5
- 108010038795 estrogen receptors Proteins 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims description 4
- 239000001393 triammonium citrate Substances 0.000 claims description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 3
- 239000012828 PI3K inhibitor Substances 0.000 claims description 3
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 3
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 3
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims description 2
- 102000007594 Estrogen Receptor alpha Human genes 0.000 claims 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 2
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- 229960002932 anastrozole Drugs 0.000 claims 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 2
- 229960000255 exemestane Drugs 0.000 claims 2
- 229960003881 letrozole Drugs 0.000 claims 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 claims 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662406859P | 2016-10-11 | 2016-10-11 | |
| US62/406,859 | 2016-10-11 | ||
| US201762457759P | 2017-02-10 | 2017-02-10 | |
| US62/457,759 | 2017-02-10 | ||
| US201762502299P | 2017-05-05 | 2017-05-05 | |
| US62/502,299 | 2017-05-05 | ||
| PCT/US2017/055970 WO2018093484A1 (en) | 2016-10-11 | 2017-10-10 | Lasofoxifene treatment of er+ breast cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021022514A Division JP7247241B2 (ja) | 2016-10-11 | 2021-02-16 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529581A JP2019529581A (ja) | 2019-10-17 |
| JP2019529581A5 true JP2019529581A5 (enExample) | 2020-11-19 |
| JP6892151B2 JP6892151B2 (ja) | 2021-06-23 |
Family
ID=60186386
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540308A Active JP6892151B2 (ja) | 2016-10-11 | 2017-10-10 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
| JP2021022514A Active JP7247241B2 (ja) | 2016-10-11 | 2021-02-16 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
| JP2023003699A Active JP7418052B2 (ja) | 2016-10-11 | 2023-01-13 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
| JP2023219161A Active JP7774896B2 (ja) | 2016-10-11 | 2023-12-26 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021022514A Active JP7247241B2 (ja) | 2016-10-11 | 2021-02-16 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
| JP2023003699A Active JP7418052B2 (ja) | 2016-10-11 | 2023-01-13 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
| JP2023219161A Active JP7774896B2 (ja) | 2016-10-11 | 2023-12-26 | Ｅｒ＋乳がんのラソフォキシフェン処置 |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US20190231718A1 (enExample) |
| EP (2) | EP3525774B1 (enExample) |
| JP (4) | JP6892151B2 (enExample) |
| KR (5) | KR20240007720A (enExample) |
| CN (3) | CN112353796A (enExample) |
| AU (3) | AU2017360365B2 (enExample) |
| BR (1) | BR112019007254A2 (enExample) |
| CA (1) | CA3040266A1 (enExample) |
| DK (1) | DK3525774T3 (enExample) |
| ES (1) | ES2909576T3 (enExample) |
| IL (2) | IL284875B (enExample) |
| MX (2) | MX387856B (enExample) |
| NZ (2) | NZ752443A (enExample) |
| PL (1) | PL3525774T3 (enExample) |
| PT (1) | PT3525774T (enExample) |
| RU (1) | RU2019114079A (enExample) |
| SG (2) | SG11201903236SA (enExample) |
| TW (4) | TWI790672B (enExample) |
| WO (2) | WO2018093484A1 (enExample) |
| ZA (1) | ZA201902454B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| BR112019007254A2 (pt) | 2016-10-11 | 2019-07-02 | Duke University | tratamento lasofoxifeno de câncer de mama er+ |
| WO2019199891A1 (en) | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| TW202410890A (zh) * | 2022-05-25 | 2024-03-16 | 美商神莫尼克斯製藥公司 | 使用ｃｄｋ４／６抑制劑後發展之ｅｒ⁺乳癌之拉索昔芬（ｌａｓｏｆｏｘｉｆｅｎｅ）組合治療 |
| WO2025075631A1 (en) | 2023-10-06 | 2025-04-10 | Sermonix Pharmaceuticals, Inc. | Lasofoxifene treatment of endocrine therapy resistant er+ cancer |
| WO2025099482A1 (en) * | 2023-11-06 | 2025-05-15 | Centro De Investigación Y De Estudios Avanzados Del I.P.N. | Synergistic loratadine-raloxifene-sorafenib compositions for the treatment of hepatic cancer |
| WO2025122504A1 (en) * | 2023-12-04 | 2025-06-12 | Foundation Medicine, Inc. | Esr1 mutations, esr1 co-occurring mutations, and uses thereof |
| WO2025165887A1 (en) * | 2024-01-30 | 2025-08-07 | Sermonix Pharmaceuticals, Inc. | Lasofoxifene treatment of er+ cancers with constitutively active esr1 mutations |
| CN119842900A (zh) * | 2025-01-17 | 2025-04-18 | 厦门飞朔生物技术有限公司 | 一种可用于乳腺癌内分泌耐药治疗指导的人esr1基因突变检测试剂盒 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| UA51676C2 (uk) | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| US20040044080A1 (en) | 1997-10-28 | 2004-03-04 | Place Virgil A. | Treatment of dyspareunia with topically administered nitroglycerin formulations |
| WO1999065498A1 (en) | 1998-06-19 | 1999-12-23 | Senju Pharmaceutical Co., Ltd. | Agents for relieving side effects of adrenal cortex hormone |
| YU26700A (sh) | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
| EP1086692A3 (en) | 1999-07-28 | 2003-07-09 | Pfizer Products Inc. | Estrogen agonists and antagonists for multiple indications |
| US6436977B1 (en) | 1999-09-29 | 2002-08-20 | Pfizer Inc. | Dosing regimens for lasofoxifene |
| CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| AU2991301A (en) | 2000-01-28 | 2001-08-07 | Endorecherche Inc. | Selective estrogen receptor modulators in combination with estrogens |
| DE10039199A1 (de) | 2000-08-10 | 2002-02-21 | Schering Ag | Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen |
| CN100448487C (zh) | 2000-08-11 | 2009-01-07 | 惠氏公司 | 治疗雌激素受体阳性癌的方法 |
| WO2002056903A2 (en) | 2001-01-17 | 2002-07-25 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
| AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| BR0308758A (pt) | 2002-03-28 | 2004-12-28 | Pfizer Prod Inc | Lasofoxifeno purificado e método para purificação de lasofoxifeno racêmico por recristalização |
| PA8576201A1 (es) | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
| MX368189B (es) | 2004-10-20 | 2019-09-23 | Endorecherche Inc | Precursores esteroides sexuales solos o en combinación con un modulador receptor de estrógeno selectivo y/o con estrógenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevención y tratamiento de sequedad vaginal y disfunción sexual en mujeres post-menopáusicas. |
| US20090012052A1 (en) | 2006-11-09 | 2009-01-08 | Ore Pharmaceuticals Inc. | Method for treating er+ breast cancer |
| US20110015134A1 (en) | 2007-04-16 | 2011-01-20 | Retsky Michael W | Method of treatment for early stage cancer |
| CZ2007373A3 (cs) | 2007-05-29 | 2008-12-10 | Zentiva, A. S | Zpusob prípravy lasofoxifenu |
| US20110182888A1 (en) | 2008-04-08 | 2011-07-28 | Peter Ordentlich | Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator |
| US20100029734A1 (en) * | 2008-05-06 | 2010-02-04 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
| MY161598A (en) | 2009-01-30 | 2017-04-28 | Glaxosmithkline Llc | Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| EP2239570A1 (en) * | 2009-04-10 | 2010-10-13 | PamGene B.V. | Method for determining the estrogen receptor status of breast cancer |
| US9351964B2 (en) * | 2009-05-27 | 2016-05-31 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
| EP2606130B1 (en) | 2010-08-16 | 2019-03-13 | Duke University | Camkk-beta as a marker in prostate cancer |
| US20120052508A1 (en) * | 2010-08-27 | 2012-03-01 | Rutgers, The State University Of New Jersey | Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies |
| JP2014508782A (ja) | 2011-03-11 | 2014-04-10 | メリマック ファーマシューティカルズ インコーポレーティッド | ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用 |
| EP2709661A4 (en) | 2011-05-18 | 2015-01-28 | Merck Sharp & Dohme | COMBINATIONS OF THERAPEUTIC ANTI-IGF1R |
| WO2013056178A2 (en) * | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
| PE20150099A1 (es) | 2011-12-16 | 2015-01-30 | Olema Pharmaceuticals Inc | Compuestos novedosos de benzopirano, composiciones y usos de los mismos |
| US20160038506A1 (en) | 2012-02-14 | 2016-02-11 | Repros Therapeutics Inc. | Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US9204286B1 (en) | 2013-03-15 | 2015-12-01 | Sprint Communications Company L.P. | System and method of branding and labeling a mobile device |
| EP3116497A2 (en) | 2014-03-13 | 2017-01-18 | F. Hoffmann-La Roche AG | Therapeutic combinations with estrogen receptor modulators |
| WO2015136017A1 (en) * | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
| PT3122426T (pt) | 2014-03-28 | 2023-02-28 | Univ Duke | Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| CN104208069A (zh) | 2014-05-08 | 2014-12-17 | 上海市计划生育科学研究所 | 双炔失碳酯组合物和疾病治疗方法 |
| EP3215137A1 (en) | 2014-11-07 | 2017-09-13 | Lipoxen Technologies Limited | Method for treatment of primary hormone resistant endometrial and breast cancers |
| US20180049999A1 (en) | 2015-04-14 | 2018-02-22 | Atossa Genetics Inc. | Compositions and methods of treatment of breast disorders and estrogen-related disorders |
| EP3288383A4 (en) | 2015-04-29 | 2019-01-23 | Radius Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
| BR112019007254A2 (pt) | 2016-10-11 | 2019-07-02 | Duke University | tratamento lasofoxifeno de câncer de mama er+ |
| US20190231743A1 (en) | 2016-10-11 | 2019-08-01 | Sermonix Pharmaceuticals, Llc | Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies |
| US10624874B2 (en) | 2017-01-10 | 2020-04-21 | Zhejiang Jiachi Development Pharmaceuticals Ltd | Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment |
| WO2019199891A1 (en) * | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
| CN113490850B (zh) * | 2018-08-17 | 2024-12-06 | 基因泰克公司 | 用于治疗乳腺癌的诊断和治疗方法 |
| CN118369116A (zh) | 2021-10-05 | 2024-07-19 | 杜克大学 | 包含肿瘤免疫的小分子调节物的组合物及其使用方法 |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| TW202410890A (zh) | 2022-05-25 | 2024-03-16 | 美商神莫尼克斯製藥公司 | 使用ｃｄｋ４／６抑制劑後發展之ｅｒ⁺乳癌之拉索昔芬（ｌａｓｏｆｏｘｉｆｅｎｅ）組合治療 |
-
2017
- 2017-10-10 BR BR112019007254-3A patent/BR112019007254A2/pt not_active Application Discontinuation
- 2017-10-10 DK DK17791239.1T patent/DK3525774T3/da active
- 2017-10-10 IL IL284875A patent/IL284875B/en unknown
- 2017-10-10 KR KR1020247000452A patent/KR20240007720A/ko active Pending
- 2017-10-10 NZ NZ752443A patent/NZ752443A/en unknown
- 2017-10-10 MX MX2019004184A patent/MX387856B/es unknown
- 2017-10-10 CN CN202011320148.5A patent/CN112353796A/zh active Pending
- 2017-10-10 KR KR1020197013405A patent/KR102285453B1/ko active Active
- 2017-10-10 KR KR1020227037620A patent/KR102623130B1/ko active Active
- 2017-10-10 SG SG11201903236SA patent/SG11201903236SA/en unknown
- 2017-10-10 NZ NZ793063A patent/NZ793063A/en unknown
- 2017-10-10 SG SG10201913951YA patent/SG10201913951YA/en unknown
- 2017-10-10 AU AU2017360365A patent/AU2017360365B2/en active Active
- 2017-10-10 CA CA3040266A patent/CA3040266A1/en active Pending
- 2017-10-10 RU RU2019114079A patent/RU2019114079A/ru unknown
- 2017-10-10 CN CN201780073528.3A patent/CN110099680B/zh active Active
- 2017-10-10 US US16/341,033 patent/US20190231718A1/en not_active Abandoned
- 2017-10-10 PT PT177912391T patent/PT3525774T/pt unknown
- 2017-10-10 WO PCT/US2017/055970 patent/WO2018093484A1/en not_active Ceased
- 2017-10-10 EP EP17791239.1A patent/EP3525774B1/en active Active
- 2017-10-10 JP JP2019540308A patent/JP6892151B2/ja active Active
- 2017-10-10 KR KR1020217023829A patent/KR102462433B1/ko active Active
- 2017-10-10 WO PCT/US2017/055974 patent/WO2018071440A1/en not_active Ceased
- 2017-10-10 US US15/729,320 patent/US20180098963A1/en not_active Abandoned
- 2017-10-10 CN CN202110143863.4A patent/CN112933082A/zh active Pending
- 2017-10-10 EP EP21215433.0A patent/EP4035662A1/en active Pending
- 2017-10-10 PL PL17791239T patent/PL3525774T3/pl unknown
- 2017-10-10 KR KR1020237008605A patent/KR102531354B1/ko active Active
- 2017-10-10 ES ES17791239T patent/ES2909576T3/es active Active
- 2017-10-11 TW TW110124571A patent/TWI790672B/zh active
- 2017-10-11 TW TW106134805A patent/TWI729227B/zh active
- 2017-10-11 TW TW111149243A patent/TWI836808B/zh active
- 2017-10-11 TW TW113106582A patent/TWI896001B/zh active
-
2018
- 2018-03-28 US US15/939,218 patent/US10258604B2/en active Active
-
2019
- 2019-02-01 US US16/265,109 patent/US10905659B2/en active Active
- 2019-04-10 MX MX2021013911A patent/MX2021013911A/es unknown
- 2019-04-10 IL IL265938A patent/IL265938B/en unknown
- 2019-04-17 ZA ZA2019/02454A patent/ZA201902454B/en unknown
-
2020
- 2020-10-16 US US17/073,253 patent/US20210361596A1/en not_active Abandoned
-
2021
- 2021-02-16 JP JP2021022514A patent/JP7247241B2/ja active Active
-
2022
- 2022-10-09 AU AU2022246480A patent/AU2022246480B2/en active Active
-
2023
- 2023-01-13 JP JP2023003699A patent/JP7418052B2/ja active Active
- 2023-03-30 US US18/193,207 patent/US11980597B2/en active Active
- 2023-12-26 JP JP2023219161A patent/JP7774896B2/ja active Active
-
2024
- 2024-04-08 US US18/629,894 patent/US20250064757A1/en active Pending
- 2024-07-04 US US18/764,274 patent/US12414924B2/en active Active
-
2025
- 2025-01-16 AU AU2025200327A patent/AU2025200327A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529581A5 (enExample) | ||
| CN108024541B (zh) | 用于治疗癌症的方法 | |
| RU2019114079A (ru) | Лечение er+ рака молочной железы лазофоксифеном | |
| JP2019518765A5 (enExample) | ||
| RU2022108295A (ru) | Способы лечения ar+ рака молочной железы | |
| WO2015082990A1 (en) | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer | |
| JP7667132B2 (ja) | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 | |
| RU2016148441A (ru) | Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом | |
| JP2019508476A5 (enExample) | ||
| JP7376540B2 (ja) | リンパ節陽性の初期ホルモン受容体陽性かつヒト上皮成長因子受容体２陰性乳癌の補助治療のための内分泌療法とアベマシクリブとの組み合わせ | |
| EA032067B1 (ru) | Совместное введение стероидов и золедроновой кислоты для профилактики и лечения остеоартрита | |
| US20240173306A1 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor | |
| CN107249587B (zh) | 用于治疗乳腺癌的抗组胺药 | |
| EP3654967A1 (en) | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer | |
| EP3919058A1 (en) | Use of composition containing cdk4/6 inhibitor in combination with anastrozole in preparation of medicament for treating tumor diseases | |
| US20230381156A1 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib | |
| JPWO2023091553A5 (enExample) | ||
| JPH09506902A (ja) | 前立線癌の化学療法剤の補助剤 | |
| US20230381154A1 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib | |
| WO2024246824A1 (en) | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer | |
| JP2023086719A (ja) | Ｃｄｋ４及び６阻害剤で以前に治療された患者におけるホルモン受容体陽性でヒト上皮成長因子受容体２陰性の進行性又は転移性乳がんの治療のためのフルベストラントとのｃｄｋ４及び６阻害剤の併用 | |
| HK40062029A (en) | Use of composition containing cdk4/6 inhibitor in combination with anastrozole in preparation of medicament for treating tumor diseases | |
| Bacalbașa et al. | NEW AGENTS IN THE FIRST LINE TREATMENT OF METASTATIC OR LOCALLY ADVANCED ENDOCRINE POSITIVE, HER-2/NEU NEGATIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN. A REVIEW | |
| Dimari et al. | Every two-weeks docetaxel in the treatment of elderly patients with advanced breast cancer | |
| JPWO2022177835A5 (enExample) |